skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Safety and efficacy of alteplase in the treatment of acute ischemic stroke

Review

(2683) Views  (1035) Full article downloads

Authors: Giuseppe Micieli, Simona Marcheselli, Piera Angela Tosi

Published Date May 2009 Volume 2009:5 Pages 397 - 409
DOI: http://dx.doi.org/10.2147/VHRM.S4561

Giuseppe Micieli, Simona Marcheselli, Piera Angela Tosi

Neurology and Stroke Unit, IRCCS Istituto Clinico Humanitas, Rozzano (MI), italy

Abstract: After publication of the results of the National Institute of Neurological Disorders and Stroke study, the application of intravenous thrombolysis for ischemic stroke was launched and has now been in use for more than 10 years. The approval of this drug represented only the first step of the therapeutic approach to this pathology. Despite proven efficacy, concerns remain regarding the safety of recombinant tissue-type plasminogen activator for acute ischemic stroke used in routine clinical practice. As a result, a small proportion of patients are currently treated with thrombolytic drugs. Several factors explain this situation: a limited therapeutic window, insufficient public knowledge of the warning signs for stroke, the small number of centers able to administer thrombolysis on a 24-hour basis and an excessive fear of hemorrhagic complications. The aim of this review is to explore the clinical efficacy of treatment with alteplase and consider the hemorrhagic risks.

Keywords: rt-PA, acute ischemic stroke, intracranial hemorrhage








Readers of this article also read:

Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Treatment of pediatric pulmonary hypertension
Dronedarone for atrial fibrillation: a new therapeutic agent
Comparative assessment of angiotensin receptor blockers in different clinical settings
Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
Cardiac risk stratification: Role of the coronary calcium score
Management of acute attacks of hereditary angioedema: potential role of icatibant
Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University